BackgroundLinezolid is a new antimicrobial agent with a broad spectrum of activity against all clinically important gram positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE). The incidence of linezolid induced thrombocytopenia was reported to be 2.4% in phase III trials. Clearance of linezolid is not altered in patents with renal insufficiency and no dose adjustment is necessary. Therefore, linezolid is a suitable and reasonable drug of choice for patients with renal insufficiency who have MRSA or VRE infection. Moreover, renal insufficiency is also known to cause thrombocytopenia.PurposeThis study investigated if the incidence of linezolid induced thrombocytopenia in a patient with renal insufficiency was higher than that of others with normal renal function.Material and methodsThe case report was in relation to severe thrombocytopenia (platelet count <100 × 109 platelets/L) in a patient with haemodialysis who was treated with linezolid for VRE infection. Then, a retrospective study was performed in patients treated with linezolid and to evaluate the incidence of linezolid induced thrombocytopenia.Results16 patients (10 females), with mean age of 64.8 years, were studied between August 2014 and August 2015. The samples size was small because of the limitations of using linezolid imposed by the national healthy insurance of Taiwan. 6 patients had decreased platelet count of >25% from baseline during treatment with linezolid and 4 (67%) had renal insufficiency (creatinine clearance <50 mL/min). Two patients with renal insufficiency had severe thrombocytopenia.ConclusionThe results showed that the incidence of linezolid induced thrombocytopenia was higher in patients with renal insufficiency. Clinicians should consider the potential risks of linezolid treatment and monitor closely platelet count in during linezolid treatment. Further studies should be encouraged to determine if dose adjustment of linezolid in renal insufficiency is necessary to reduce the incidence of linezolid related thrombocytopenia.References and/or AcknowledgementsClin Infect Dis 2006;42:66-72Int J Antimicrob Agents 2008;28:345-51Int J Antimicrob Agents 2014;44:242-7Eur J Clin Pharmacol 2014;70:23-8J Infect Chemother 2011;17:382-7This study was financially supported by the Department of Pharmacy, Kaohsiung Municipal Hsiao-Kang Hospital.No conflict of interest.
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, accompanied by a characteristic neuropsychiatric syndrome, predominantly affects young women with ovarian tumors. Although the initial onset of isolated psychiatric symptoms is rare, most cases of anti-NMDAR encephalitis are initially seen by psychiatrists in an emergency room (ER) setting. Furthermore, many of these cases are misdiagnosed as psychiatric disorders. In this report, we discuss a case of a 15-year-old female patient with anti-NMDAR encephalitis. The patient had an initial presentation of sudden-onset regressive behaviour, which is seldom mentioned in the literature. This case may serve as a reminder to psychiatrists, especially ER psychiatrists who are often the first to witness the changing phases of anti-NMDAR encephalitis-associated psychiatric symptoms, to widen the clinical spectrum of this disease. (Hong Kong j.emerg.med. 2016;23:242-245)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.